Frank Placencia
Biographic Data
| ID | 9596269 |
|---|---|
| NAME | Frank Placencia |
| GIVEN NAMES | Frank |
| FAMILY NAME | Placencia |
| SIGNATURE | PLACENCIA F |
| AFFILIATIONS | Baylor College of Medicine |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
No prominent works on this page.
Harm reduction in paediatric off-label therapy
Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and…
Best interests (1 work) · Cystic fibrosis (1 work) · Cystic Fibrosis Research Advances (1 work) · Cystic fibrosis transmembrane conductance regulator (1 work) · Disease (1 work) · Do no harm (1 work) · Ethics and Legal Issues in Pediatric Healthcare (1 work) · Genetic testing (1 work) · Harm (1 work) · Newborn screening (1 work)